Form 10-Q Summit Therapeutics Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Summit Therapeutics: substantial doubt about our ability to continue as a going concern
July 23, 2026 4:25 PM EDTFrom Summit Therapeutics' (NASDAQ: SMMT) 10-Q filing on Thursday:
During the three and six months ended June 30, 2026, we incurred a net loss of $215.7 million and $405.1 million and cash flows used in operating activities for the six months ended June 30, 2026 was $263.4 million. As of June 30, 2026, we had an accumulated deficit of $2,699.3 million, cash and cash equivalents of $419.4 million and short-term... More
